How does entrectinib work?

Entrectinib, a targeted therapy drug developed by Genentech, a member of the Roche Group, is unique in that it can precisely inhibit tyrosine kinase activity in tumor cells. Tyrosine kinase plays a key role in the proliferation, metastasis and spread of tumor cells, and entrectinib inhibits the activity of this enzyme, effectively blocking the growth and spread pathways of tumor cells, thereby achieving the purpose of treating cancer.

In clinical trials, the therapeutic effects of entrectinib have been impressive. Especially in the treatment of patients with ROS1 fusion-positive non-small cell lung cancer and NTRK gene fusion-positive solid tumors, entrectinib has shown significant effects. The patient's objective response rate has reached a high level, and the median sustained response time and median progression-free survival have also been significantly prolonged. These results fully demonstrate the efficacy of entrectinib in the treatment of specific types of cancer.

In addition, entrectinib has the ability to cross the blood-brain barrier, which makes it uniquely advantageous for the treatment of brain metastatic cancer. Many cancer patients will develop brain metastases during the progression of the disease. However, traditional anti-cancer drugs often have difficulty crossing the blood-brain barrier and cannot have an effective effect on brain metastasis cancer cells. This property of entrectinib makes it an effective drug for the treatment of brain metastatic cancer.

However, it is worth noting that entrectinib also has some potential adverse reactions, such as diarrhea, rash, itching, etc. Therefore, when using entrectinib for treatment, patients need to take the medication under the guidance of a doctor and pay close attention to their physical condition.

Overall, entrectinib has demonstrated outstanding performance in the field of anti-cancer drugs due to its unique efficacy and mechanism of action. With the deepening of clinical research and the continuous optimization of drugs, entrectinib is expected to bring treatment hope to more cancer patients. In addition, entrectinib has been launched in China, and patients can consult local hospitals for specific price and drug purchase information. At the same time, generic drugs of entrectinib are also available overseas, and the price is relatively affordable. Patients should make their own choices based on their own circumstances.